所有图片(1)
About This Item
经验公式（希尔记法）:
C21H24FN3O4· HCl
CAS号:
分子量:
437.89
Beilstein:
8377447
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D -119 to -139°, c = 0.5 in water
儲存條件
desiccated
顏色
white to beige
溶解度
H2O: 5 mg/mL, clear (warmed)
儲存溫度
−20°C
SMILES 字串
Cl.COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(O)=O
InChI
1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1
InChI 密鑰
IDIIJJHBXUESQI-DFIJPDEKSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
莫西沙星是第四代合成氟喹诺酮类抗菌剂。莫西沙星与其他喹诺酮类药物不同，其是一种8-甲氧基喹诺酮。
應用
盐酸莫西沙星已被用于研究其对已生长至高密度细菌的抗菌作用。
生化／生理作用
莫西沙星已被证明可有效治疗鼻窦炎、社区获得性呼吸道感染、肺炎和慢性支气管炎的急性加重。与其他氟喹诺酮（如环丙沙星和氧氟沙星）相比，它具有更好的抗革兰氏阳性活性。莫西沙星可用于治疗细菌性皮肤感染。它可以适当渗透到周围组织和炎性液体中。氟喹诺酮类可通过与酶-DNA复合物结合来稳定由DNA回旋酶和拓扑异构酶IV产生的DNA链断裂。 与哺乳动物DNA促旋酶相比，莫西沙星对细菌DNA促旋酶的亲和力高100倍。莫西沙星是一种抗生素，可抗革兰氏阳性和革兰氏阴性细菌。莫西沙星在治疗耐多药结核病中的研究正在进行中。
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Edward D Chan et al.
American journal of respiratory and critical care medicine, 169(10), 1103-1109 (2004-01-27)
Multidrug-resistant tuberculosis, a disease caused by Mycobacterium tuberculosis strains that are resistant at least to rifampin and isoniazid, entails extended treatment, expensive and toxic regimens, and higher rates of treatment failure and death. We retrospectively analyzed the outcomes in 205
An HPLC Method for the Determination of Moxifloxacin in Breast Milk by Fluorimetric Detection with Precolumn Derivatization.
Tekkeli SEK
Acta Chromatographica , 10-10 (2016)
Moxifloxacin.
Muijsers R B and Jarvis B
Drugs, 62(6), 967-973 (2002)
Stephen H Gillespie
European respiratory review : an official journal of the European Respiratory Society, 25(139), 19-28 (2016-03-02)
Tuberculosis (TB) remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate
Francis S Mah
Current opinion in ophthalmology, 15(4), 316-320 (2004-07-03)
The fourth-generation fluoroquinolones, moxifloxacin and gatifloxacin, were introduced in 2003 promising improved spectrum of activity and delayed development of resistance. Although these topical agents have recently been introduced in commercial form, there is already a growing body of evidence showing
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门